QUALITY OF LIFE IN PATIENTS TREATED WITH STEREOTACTIC ABLATIVE BODY RADIOTHERAPY (SABR) FOR LIVER METASTASES

Isabelle Thibault, William Chu, Kelvin Chan, Darby Erler, Edward Chow, Hans Chung

Corresponding author: Isabelle Thibault

1. Radiation Oncology, University of Toronto 2. Radiation Oncology, University of Toronto 3. Radiation Oncology, University of Toronto 4. Radiation Oncology, University of Toronto 5. Radiation Oncology, University of Toronto

Categories: Radiation Oncology
Keywords: liver metastases, stereotactic body radiotherapy, quality of life

How to cite this poster

Abstract

Isabelle Thibault, William Chu, Kelvin Chan, Darby Erler, Edward Chow, Hans Chung
University of Toronto, Toronto, ON

Purpose: SABR is a locally ablative therapy for liver metastases associated with favorable local control rate, but data on patient-reported outcome is limited. The purpose of this prospective study is to measure quality of life (QOL) score changes after SABR in patients with liver metastases.

Materials and Methods: Patients treated with SABR to 1-3 hepatic metastases completed the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire–Core 15 Palliative (QLQ-C15-PAL) and EORTC QLQ–liver metastases (QLQ-LM21) validated questionnaires. The QLQ-LM21 is designed for patients with colorectal cancer (CRC) liver metastases treated with liver surgery or palliative treatment. The QLQ-C15-PAL is a shorter version of the QLQ-C30 core questionnaire and it was chosen to decrease the burden of completing both the longer QLQ-C30 form and the QLQ-LM21. Questionnaires were completed before, during and at one week, six weeks, and three months post-SABR. A high score represents a high QOL for the global health status, a high level of functioning for the functional scales, or a high level of symptomatology for the symptom scales.

Results: Thirty metastatic patients (15 men, 15 women) with a primary CRC (n=12), non-CRC gastro-intestinal cancer (n=8), breast cancer (n=6), or lung cancer (n=4), were accrued. Median age was 65 years (range, 40-88 years). All had Child-Pugh score of A. Questionnaire compliance was 100% at baseline and during SABR, 97% (29/30) at one week, 80% (24/30) at six weeks, and 60% (18/30) at three months. Majority of the QOL items (QLQ-C15-PAL, 12/15 [80%] items; QLQ-LM21, 21/21 [100%] items) remained stable after liver SABR for all the time points, except for increasing fatigue (mean score change, 2.0/4 to 2.3/4; p=0.049) and decreased global health status (mean score change, 5.3/7 to 5.0/7; p=0.033) both at one week post-SABR.

Conclusions: QOL remained stable after SABR in liver metastases in the majority of the QOL items (80% on the QLQ-C15-PAL, 100% on the QLQ-LM21), except for fatigue and global health status at one week post-SABR. SABR provides not only local control but also maintains QOL.